MHRA is approved for the UK's first T1D immunotherapy
The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved teprizumab (Tzield, Aventis Pharma Limited) as the UK's first immunotherapy for type 1 diabetes (T1D). The drug is approved for…